NEW YORK (GenomeWeb News) – EMD Serono announced on Tuesday a research agreement with Pfizer and the Broad Institute to genomically profile systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients.
As part of the project, being funded jointly by EMD Serono and Pfizer, the Broad will use biochemical and next-generation sequencing technologies to investigate samples from SLE and LN patients, as well as analyze immune cell subpopulations, in order to identify biomarkers to better define patient populations for future therapies.